Lilly, MiNA ink agreement to upregulate proteins using RNA
Eli Lilly will utilise the power of MiNA Therapeutics’ proprietary small activating RNA (saRNA) technology platform to develop five novel drug candidates against diseases across the company’s core areas of focus.
Eli Lilly declared a drug development collaboration that could be worth up to USD 245 million per target for the London-based MiNA Therapeutics Limited.
Under terms of the deal, MiNA will use its saRNA platform to research up to five targets chosen by Lilly. The Indianapolis-based company will then be responsible for the preclinical and clinical development of candidates and will retain...
